Revive Therapeutics Ltd. has closed a second tranche of its private placement, issuing 4,352,381 units at $0.021 per unit, generating $91,400. Each unit includes one common share and one warrant to purchase a common share at $0.05 within 36 months. The funds will be used for working capital and trade payables. All securities are subject to a hold period until January 19, 2026. Revive focuses on developing therapeutics for critical medical needs, including Bucillamine for infectious diseases and medical countermeasures, Psilocybin, and molecular hydrogen programs. For more information, visit www.ReviveThera.com. Contact CEO Michael Frank at [email protected] or 1 888 901 0036.

Read more at Globe Newswire: Revive Therapeutics Announces Closing of Second Tranche of